Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-04, Stock:ABBV, The news for the past five days is as follows:
2018-05-25: NEWS1: After Hours Most Active for May 25, 2018 :  ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC.NEWS2: After Hours Most Active for May 25, 2018 :  ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC.NEWS3: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS4: AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint.NEWS5: AbbVie&apos;s Imbruvica&apos;s Phase III Study Meets Primary Endpoint.NEWS6: Analyzing Ionis’s Q1 Revenue Streams.
2018-05-29: NEWS1: After Hours Most Active for May 29, 2018 :  BAC, GE, CSCO, MSFT, JPM, QQQ, ABBV, WFC, SO, QCOM, FOXA, PEP.NEWS2: After Hours Most Active for May 29, 2018 :  BAC, GE, CSCO, MSFT, JPM, QQQ, ABBV, WFC, SO, QCOM, FOXA, PEP.NEWS3: What's in Store for Cooper Companies' (COO) Q2 Earnings?.NEWS4: What's in Store for Cooper Companies' (COO) Q2 Earnings?.NEWS5: What&apos;s in Store for Cooper Companies&apos; (COO) Q2 Earnings?.NEWS6: AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference.
2018-05-30: NEWS1: AbbVie Announces Updated Preliminary Results of Tender Offer.NEWS2: Why AbbVie&apos;s Blockbuster Humira Is Already In Trouble This Year.NEWS3: Health Care Sector Update for 05/30/2018: EXAS,ABBV,CTRV,TXMD.NEWS4: Health Care Sector Update for 05/30/2018: EXAS,ABBV,CTRV,TXMD.NEWS5: Noteworthy Wednesday Option Activity: ABBV, GS, DG.NEWS6: Noteworthy Wednesday Option Activity: ABBV, GS, DG.NEWS7: Health Care Sector Update for 05/30/2018: ABBV,CTRV,TXMD.NEWS8: Health Care Sector Update for 05/30/2018: ABBV,CTRV,TXMD.NEWS9: AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why.NEWS10: AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why.NEWS11: Credit Suisse Downgrades AbbVie On Humira Competitive Concerns.NEWS12: Pre-Market Most Active for May 30, 2018 :  ABBV, DKS, TVIX, MU, BAC, TXMD, TLT, QQQ, AKS, DB, CHK, SQQQ.NEWS13: Pre-Market Most Active for May 30, 2018 :  ABBV, DKS, TVIX, MU, BAC, TXMD, TLT, QQQ, AKS, DB, CHK, SQQQ.NEWS14: AbbVie Announces Preliminary Results of Tender Offer.NEWS15: How Are Merck’s Virology and Immunology Segments Positioned?.NEWS16: Is AbbVie Inc. (ABBV) a Buy?.NEWS17: Is AbbVie Inc. (ABBV) a Buy?.NEWS18: Is AbbVie Inc. (ABBV) a Buy?.
2018-05-31: NEWS1: Gilead & Galapagos Announce Positive Data on Filgotinib.NEWS2: Gilead & Galapagos Announce Positive Data on Filgotinib.NEWS3: Thursday’s Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV).NEWS4: Thursday’s Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV).NEWS5: Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis.NEWS6: Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis.NEWS7: Traders Are Furious After Computer Botches Stock Sale.NEWS8: Thursday’s Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV).NEWS9: AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress.
2018-06-01: NEWS1: After Hours Most Active for Jun 1, 2018 :  ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT.NEWS2: After Hours Most Active for Jun 1, 2018 :  ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT.NEWS3: Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone.NEWS4: How Novartis, Insurers Are Taking Wind Out Of AbbVie&apos;s Sales.NEWS5: Solid Month Ends with New Round of Trade Fears.NEWS6: Solid Month Ends with New Round of Trade Fears.NEWS7: Solid Month Ends with New Round of Trade Fears.NEWS8: Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod.NEWS9: Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod.

Answer: Rise